

File 351:Derwent WPI 1963-2001/UD,UM &UP=200211
(c) 2002 Derwent Info Ltd

Set Items Description

?s pn,an=jp,2625457

1 PN=JP 2625457

0 AN=JP 2625457

S1

1 PN,AN=JP 2625457

?t 1/3,ab/all

1/3,AB/1

DIALOG(R)File 351:Derwent WPI

(c) 2002 Derwent Info Ltd. All rts. reserv.

007894947

WPI Acc No: 1989-160059/198922

Related WPI Acc No: 1988-028629

XRAM Acc No: C89-070912

Quat derivs. of noroxymorphone - administered enterally before
anaesthetic analgesic, for preventing nausea etc.

Patent Assignee: UNIV CHICAGO (UYCH-N)

Inventor: GOLDBERG L I

Number of Countries: 004 Number of Patents: 006

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 1068376	A	19890314	JP 87330356	A	19871228	198922 B
DK 8706933	A	19890304				198923
US 4861781	A	19890829	US 8792470	A	19870903	198944
CA 1315689	C	19930406	CA 548964	A	19871009	199319
DK 167340	B	19931018	DK 876933	A	19871230	199347
JP 2625457	B2	19970702	JP 87330356	A	19871228	199731

Priority Applications (No Type Date): US 8792470 A 19870903; US 86837399 A
19860307

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 1068376	A		4	P	
DK 167340	B			P	Previous Publ. patent DK 8706933
JP 2625457	B2		3	P	Previous Publ. patent JP 1068376
DK 8706933	A			P	
US 4861781	A			P	
CA 1315689	C			P	

Abstract (Basic): JP 1068376 A

Prevention and reduction of nausea and emesis caused from the usage
of an anaesthetic analgesic to the homotherm; which comprises an
administration of one or more of the compound (I) with an effective
amount, before the administration of the anaesthetic analgesic or at
the simultaneous use of the analgesic.

In (I) R = allyl or relative allyl such as chloroallyl,
cyclopropyl-methyl or propargyl; X = acidic anion, esp. anion chloride,
anion bromide, anion iodide or methylsulphate anion.).

Dose of the compound is 0.05 mg/kg - 1.0 mg/kg, based on 1 mg/kg
of morphine. The cpd. is administered to the entrails. The cpd. is
administered to outside of enteron with an injection, within two hours
before the administration of the anaesthetic analgesic. The cpd. (I) is

methyl naltoloxone..

USE/ADVANTAGE- For prevention and redn. of nausea and emesis caused from the use of morphine. (Provisional Basic previously advised in week 8916)

Abstract (Equivalent): US 4861781 A

Pharmaceutical compsn. contains one or more quat. nor-hydroxymorphinone derivs. of formula (I), dispersed with the usual carriers and opt. additives. In (I), R is allyl, chloroallyl, propargyl or cyclopropylmethyl; and X is an anion, pref. halide or methosulphate.

USE- Cpds. (I) are used in dosages about 0.05-0.25 mg/kg to prevent or relieve nausea and emesis arising from the